Gilead Sciences, Inc. (GILD)
NASDAQ: GILD · Real-Time Price · USD
155.41
+8.18 (5.56%)
Feb 11, 2026, 1:13 PM EST - Market open
Gilead Sciences Employees
Gilead Sciences had 17,600 employees as of December 31, 2024. The number of employees decreased by 400 or -2.22% compared to the previous year.
Employees
17,600
Change (1Y)
-400
Growth (1Y)
-2.22%
Revenue / Employee
$1,672,898
Profits / Employee
$483,523
Market Cap
192.81B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 17,600 | -400 | -2.22% |
| Dec 31, 2023 | 18,000 | 1,000 | 5.88% |
| Dec 31, 2022 | 17,000 | 2,600 | 18.06% |
| Dec 31, 2021 | 14,400 | 800 | 5.88% |
| Dec 31, 2020 | 13,600 | 2,600 | 23.64% |
| Jan 31, 2019 | 11,000 | 1,000 | 10.00% |
| Jan 31, 2018 | 10,000 | 1,000 | 11.11% |
| Jan 31, 2017 | 9,000 | 1,000 | 12.50% |
| Jan 31, 2016 | 8,000 | 1,000 | 14.29% |
| Jan 31, 2015 | 7,000 | 900 | 14.75% |
| Jan 31, 2014 | 6,100 | 1,100 | 22.00% |
| Jan 31, 2013 | 5,000 | 500 | 11.11% |
| Jan 31, 2012 | 4,500 | 500 | 12.50% |
| Jan 31, 2011 | 4,000 | 148 | 3.84% |
| Jan 31, 2010 | 3,852 | 411 | 11.94% |
| Jan 31, 2009 | 3,441 | 462 | 15.51% |
| Jan 31, 2008 | 2,979 | 464 | 18.45% |
| Jan 31, 2007 | 2,515 | 615 | 32.37% |
| Jan 31, 2006 | 1,900 | 246 | 14.87% |
| Feb 28, 2005 | 1,654 | 229 | 16.07% |
| Feb 27, 2004 | 1,425 | 175 | 14.00% |
| Feb 28, 2003 | 1,250 | 250 | 25.00% |
| Feb 28, 2002 | 1,000 | 150 | 17.65% |
| Feb 28, 2001 | 850 | 90 | 11.84% |
| Dec 31, 1999 | 760 | 467 | 159.39% |
| Dec 31, 1998 | 293 | 4 | 1.38% |
| Dec 31, 1997 | 289 | 41 | 16.53% |
| Dec 31, 1996 | 248 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,100 |
| AstraZeneca | 92,900 |
| Sanofi | 82,878 |
| Pfizer | 81,000 |
| Novartis AG | 75,267 |
| Merck & Co. | 75,000 |
| Novo Nordisk | 69,505 |
| GSK plc | 68,629 |
GILD News
- 4 hours ago - Gilead Analysts Boost Their Forecasts After Upbeat Q4 Earnings - Benzinga
- 16 hours ago - Gilead Sciences, Inc. (GILD) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 19 hours ago - Gilead Stock Slips After Q4 Earnings, Weak FY26 Guidance - Benzinga
- 20 hours ago - Gilead Sciences Profit Rises on Growth of Liver Disease, HIV Products - WSJ
- 21 hours ago - Gilead quarterly results beat Wall Street estimates - Reuters
- 21 hours ago - Gilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 Dividend - Business Wire
- 21 hours ago - Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results - Business Wire
- 1 day ago - Gilead Sciences: Buy This Stock For Both Dividend And Growth - Seeking Alpha